COMPASS Pathways plc
Business
COMPASS Pathways is a biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin formulation for treating serious mental health conditions. The company focuses on treatment-resistant depression as its primary indication, with clinical development in post-traumatic stress disorder and anorexia nervosa. COMPASS retains global development and commercialization rights for COMP360 and intends to commercialize in the U.S. through its own sales and marketing capabilities, with potential partnerships in select international markets.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 118 | 119 | 88 | 65 | 44 | |
| General and administrative | 61 | 59 | 49 | 45 | 39 | |
| Total operating expenses | 179 | 178 | 137 | 110 | 83 | |
| LOSS FROM OPERATIONS: | −179 | −178 | −137 | −110 | −83 | |
| Fair value change of warrant liabilities | −123 | 0 | — | — | — | |
| Benefit from R&D tax credit | 4 | 21 | 13 | 14 | 10 | |
| Interest income | 7 | 8 | 5 | — | — | |
| Interest expense | −5 | −4 | −2 | — | — | |
| Foreign exchange gains (losses) | 3 | −1 | 4 | 821,000 | 2 | |
| Other income | 1 | 823,000 | 255,000 | — | — | |
| Total other (expense) income, net | −111 | 25 | 19 | 19 | 12 | |
| Loss before income taxes | −290 | −154 | −118 | −91 | −72 | |
| Income tax benefit (expense) | 2 | −2 | −780,000 | −408,000 | −199,000 | |
| Net loss | −288 | −155 | −119 | −92 | −72 | |
| Net loss per share attributable to ordinary shareholders - basic (in dollars per share) | −3.08 | −2.3 | −2.32 | −2.16 | −1.79 | |
| Net loss per share attributable to ordinary shareholders - diluted (in dollars per share) | −3.08 | −2.3 | −2.32 | −2.16 | −1.79 | |
| Weighted average ordinary shares outstanding - basic (in shares) | 94 | 67 | 51 | 42 | 40 | |
| Weighted average ordinary shares outstanding - diluted (in shares) | 94 | 67 | 51 | 42 | 40 | |
| Foreign exchange translation adjustment | 1 | 732,000 | −59,000 | — | — | |
| Comprehensive loss | −286 | −154 | −119 | −117 | −77 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 150 | 165 | 220 | 143 | 273 | |
| Restricted cash | 379,000 | 389,000 | 440,000 | 175,000 | 104,000 | |
| Prepaid expenses and other current assets | 42 | 36 | — | — | — | |
| Total current assets | 191 | 201 | 261 | 192 | 295 | |
| Operating lease right-of-use assets | 3 | 2 | 4 | 2 | 4 | |
| Deferred tax assets | 4 | 4 | 3 | 2 | 766,000 | |
| Long-term prepaid expenses and other assets | 12 | 7 | 7 | 1 | 213,000 | |
| Total assets | 210 | 214 | 276 | 197 | 301 | |
| Accounts payable | 15 | 12 | 6 | 5 | 3 | |
| Accrued expenses and other liabilities | 9 | 14 | 11 | 9 | 10 | |
| Debt, current portion | 18 | 6 | 0 | — | — | |
| Operating lease liabilities - current | 2 | 2 | 2 | 2 | 2 | |
| Warrant liabilities | 204 | 93 | — | — | — | |
| Total current liabilities | 248 | 34 | 20 | 16 | 15 | |
| Debt, non-current portion | 14 | 25 | 29 | — | — | |
| Operating lease liabilities - non-current | 1 | 303,000 | 2 | 418,000 | 1 | |
| Total liabilities | 263 | 59 | 50 | 16 | 16 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Ordinary shares, 0.008 par value; 96,085,785 and 68,552,215 shares authorized, issued and outstanding at December 31, 2025 and 2024, respectively | 973,000 | 702,000 | 635,000 | — | — | |
| Additional paid-in capital | 784 | 705 | 622 | 459 | 445 | |
| Accumulated other comprehensive loss | −15 | −16 | −17 | −17 | 9 | |
| Accumulated deficit | −823 | −535 | −380 | −261 | −170 | |
| Total shareholders' (deficit)/equity | −53 | 155 | 226 | 181 | 284 | |
| Total liabilities and shareholders' (deficit)/equity | 210 | 214 | 276 | 197 | 301 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 216,000 | 233,000 | 242,000 | — | — | |
| Non-cash interest | 1 | 1 | 636,000 | 0 | 0 | |
| Non-cash gain (loss) on foreign currency remeasurement | −1 | 755,000 | −3 | 1 | 22,000 | |
| Non-cash share-based compensation | 14 | 20 | 17 | 13 | 9 | |
| Non-cash lease expenses | 2 | 2 | 2 | 2 | 2 | |
| Transaction costs allocated to warrants | 6 | 0 | — | — | — | |
| Prepaid expenses and other current assets | −3 | 3 | 10 | −29 | −9 | |
| Deferred and prepaid tax assets | 23,000 | 686,000 | −2 | −2 | −877,000 | |
| Other assets | −5 | 135,000 | −6 | −307,000 | −160,000 | |
| Operating lease liabilities | −2 | −2 | −2 | −2 | −2 | |
| Accounts payable | 2 | 7 | 864,000 | 2 | −163,000 | |
| Accrued expenses and other liabilities | −6 | 3 | 2 | −314,000 | 5 | |
| Net cash used in operating activities | −157 | −119 | −97 | −105 | −68 | |
| Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs | 140 | 26 | 145 | 440,000 | 155 | |
| Proceeds from the exercise of warrants | 0 | 37 | 0 | — | — | |
| Proceeds from the vesting of restricted share units | 1,000 | 0 | — | — | — | |
| Payments of withholding tax on stock award | 0 | −239,000 | −265,000 | 0 | 0 | |
| Proceeds from the issuance of shares under the employee share purchase plan | 319,000 | 365,000 | 351,000 | 199,000 | 0 | |
| Proceeds from exercise of options | 35,000 | 221,000 | 2,000 | 401,000 | 2 | |
| Net cash provided by financing activities | 141 | 64 | 174 | 1 | 157 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1 | 194,000 | 867,000 | −25 | −6 | |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | −15 | −55 | 77 | −130 | 83 | |
| Cash paid for interest | 3 | 3 | 1 | 0 | 0 | |
| Cash paid for taxes | 755,000 | 1 | 2 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is COMPASS Pathways plc's CIK number?
COMPASS Pathways plc's SEC CIK number is 0001816590 (1816590). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find COMPASS Pathways plc's SEC filings?
All of COMPASS Pathways plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did COMPASS Pathways plc last report earnings?
COMPASS Pathways plc (CMPS) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001816590-26-000043). This is COMPASS Pathways plc's most recent earnings filing of record — not a forecast of its next earnings date.
What is COMPASS Pathways plc's most recent earnings 8-K?
COMPASS Pathways plc's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001816590-26-000043. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View COMPASS Pathways plc's latest earnings 8-K →
Look up any company's CIK number →